Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Atypon full text link Atypon Free PMC article
Full text links

Actions

Share

.2020 Nov-Dec;14(6):1557988320966536.
doi: 10.1177/1557988320966536.

Characteristics and Attitudes of Men Using Anabolic Androgenic Steroids (AAS): A Survey of 2385 Men

Affiliations

Characteristics and Attitudes of Men Using Anabolic Androgenic Steroids (AAS): A Survey of 2385 Men

Alex K Bonnecaze et al. Am J Mens Health.2020 Nov-Dec.

Abstract

Additional characterization of patients using anabolic androgenic steroids (AAS) is needed to improve harm reduction and cessation resources for patients. Our group sought to expand upon the currently limited data regarding AAS use by performing a web-based survey assessing experiences of males using AAS. Participants included men over the age of 18 with history of AAS use within the past 5 years. Data were collected between August 2019 and April 2020. Primary outcome measures included age when starting AAS, dose of AAS, motivations for use, experiences with health-care professionals, and rate of successful cessation. The survey was accessed 3640 times, resulting in 2385 completed surveys meeting the inclusion criteria (68.93% participation rate).Average participant age was 31.69 ± 10.09 years. Over half of respondents were from the United States (n = 1271, 53.3%). Motives to use AAS included improving appearance (n = 1959, 82.2%), strength gain (n = 1192, 50%), and self-esteem/body image issues (n = 712, 29.87%). Participants rated physicians poorly, regarding knowledge of AAS (4.08 ± 2.23). Most participants did not reveal AAS use to their health-care providers (n = 1338, 56.1%); of those that did, 55.30% (n = 579) reported feeling discriminated against for their use. Of 46.16% (n = 1101) attempting AAS cessation, 60.22% (n = 663) were unsuccessful. Challenges in the management of AAS use include early onset of use, supraphysiologic doses used, and frequently present body image disorders stress. Distrust of health-care providers, poor cessation rates, and lack of physician training further exacerbate this. These findings should serve to reinforce previous calls to action for further research on the treatment of AAS use disorder.

Keywords: anabolic androgenic steroids; anabolic steroid use; androgen abuse.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Alex K Bonnecaze and Joseph A Aloi have no disclosures or COI to disclose. Thomas O’ Connor owns and operates an internal medicine private practice based out of Essex, CT, and has written a book on the health consequences of androgen misuse.

Figures

Figure 1.
Figure 1.
Attempted AAS cessation. AAS = anabolic androgenic steroid.
Figure 2.
Figure 2.
Rated knowledge of AAS use of various groups. AAS = anabolic androgenic steroid.
Figure 3.
Figure 3.
Reporting of AAS use to medical professionals. AAS = anabolic androgenic steroid.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Achar S., Rostamian A., Narayan S. M. (2010). Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. The American Journal of Cardiology, 106(6), 893–901. 10.1016/j.amjcard.2010.05.013 - DOI - PMC - PubMed
    1. Alizade E., Avci A., Tabakcı M. M., Toprak C., Zehir R., Acar G., Kargin R., Emiroğlu M. Y., Akçakoyun M., Pala S. (2016). Comparison of right ventricle systolic function between long-term anabolic-androgenic steroid user and nonuser bodybuilder athletes: A study of two-dimensional speckle tracking echocardiography. Echocardiography (Mount Kisco, N.Y.), 33(8), 1178–1185. 10.1111/echo.13243 - DOI - PubMed
    1. Anawalt B. D. (2019). Diagnosis and management of anabolic androgenic steroid use. The Journal of Clinical Endocrinology and Metabolism. 10.1210/jc.2018-01882 - DOI - PMC - PubMed
    1. Baggish A. L., Weiner R. B., Kanayama G., Hudson J. I., Lu M. T., Hoffmann U., Pope H. G. (2017). Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation, 135(21), 1991–2002. 10.1161/CIRCULATIONAHA.116.026945 - DOI - PMC - PubMed
    1. Bertozzi G., Salerno M., Pomara C., Sessa F. (2019). Neuropsychiatric and behavioral involvement in AAS abusers. A literature review. Medicina (Kaunas, Lithuania), 55(7). 10.3390/medicina55070396 - DOI - PMC - PubMed

MeSH terms

Substances

Related information

LinkOut - more resources

Full text links
Atypon full text link Atypon Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp